Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II open-label study of IN10018 combination therapy in previously treated advanced or metastatic solid tumors
CTR20220198Phase 2Active
- Sponsor
- InnoCare Pharma
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ifebemtinib in Nonhematologic neoplasms, triple-negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC), ovarian cancer, fallopian tube cancer (PFTC), sponsored by InnoCare Pharma. Started Mar 2022; status: active.
02
Drugs
ifebemtinib
03
Conditions
Nonhematologic neoplasmstriple-negative breast cancer (TNBC)head and neck squamous cell carcinoma (HNSCC)ovarian cancerfallopian tube cancer (PFTC)
Beyond the preview
Go deeper on CTR20220198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220198.